Physician profile
Michael Haliday
NPI 1336521616
$1,000.39
in general payments reported to CMS, 2019-2025
14 companies · $199 in 2025
The $199 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $203 · 2023: $353 · 2024: $247 · 2025: $199.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $798.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $797.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $203.84 | 2022-2025 | |
| Abbvie INC. | $164.05 | 2023-2025 | |
| Amgen INC. | $127.57 | 2024 | |
| Sobi, INC | $120.27 | 2022 | |
| Gilead Sciences, INC. | $100.20 | 2022-2024 | Trodelvy |
| Pfizer INC. | $95.21 | 2022-2025 | |
| Janssen Biotech, INC. | $53.16 | 2023-2024 | Tecvayli, Carvykti |
| Incyte Corporation | $25.59 | 2025 | Jakafi |
| Seagen INC. | $22.13 | 2022 | |
| Daiichi Sankyo INC. | $19.61 | 2024 | Enhertu |
| Stemline Therapeutics INC. | $18.09 | 2023 | Orserdu |
| Merck Sharp & Dohme LLC | $17.89 | 2023 | Keytruda, Lynparza |
| Mirati Therapeutics, INC. | $16.70 | 2023 | Krazati |
| Regeneron Healthcare Solutions, INC. | $16.08 | 2023 | Libtayo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Haliday listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.